Nexalin Technology Reveals Favorable Findings from Clinical Study on Gen-2 tACS Device

Nexalin’s tACS Device Shows Effectiveness in Reducing Pain in Veteran Patients with Mild Traumatic Brain Injury: Study Results

The study was conducted at The University of California, San Diego, in collaboration with the United States Department of Veterans Affairs San Diego Healthcare System and the Radiology, Psychiatry, and Neurosciences Departments of UC San Diego. It aimed to evaluate Nexalin’s Gen-2 tACS device for reducing pain in veteran patients with Mild Traumatic Brain Injury (mTBI).

The results from this study were positive, and they demonstrate that Nexalin’s tACS device is an effective treatment option for reducing pain in veteran patients with mTBI. The clinical trial involved 24 veteran patients who received twelve sessions of either active or sham tACS over four consecutive weeks. These sessions were followed by a four-week follow-up period to assess outcomes.

The study was randomized, double-blind, and placebo-controlled, which ensured that the results were reliable and accurate. The fact that the study had a substantial market potential makes it even more significant. According to Global Market Insights, the Traumatic Brain Injuries Assessment Market is projected to reach over $7.2 billion by 2032.

Nexalin’s innovative approach offers hope for individuals suffering from mTBI by potentially improving their quality of life and providing an effective treatment option in the future. For more information about Nexalin Technology or their Gen-2 tACS device for treating mTBI, please contact Proactive North America at +1 604-688-8158 or email

Leave a Reply

How Umbrellas Influence Creative Philosophy in Sports Previous post Unreal Engine Transforms Creative Philosophy in Sports Graphics: Insights from Industry Leaders
Von der Leyen receives internal backlash for choice of business envoy – POLITICO Next post Unfair Selection: Political Rivalries Caught in EU Commission’s Decision-Making Process